OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Patel on Choosing a Chemoimmunotherapy Treatment in NSCLC

December 6th 2022

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Dr. Rocconi on the Impact of the SORAYA Trial in FRα+ Ovarian Cancer Treatment

December 6th 2022

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

December 6th 2022

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Dr. Kamath on the Prevalence of FGFR2 Fusions/Rearrangements in Cholangiocarcinoma

December 5th 2022

Suneel Kamath, MD, discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma.

Dr. Jonas on the Exploration of Uproleselan Plus Standard Therapies in AML

December 5th 2022

Brian Andrew Jonas, MD, PhD, discusses the exploration of uproleselan plus standard therapies in acute myeloid leukemia.

Dr. Fonkoua on Determining First-Line Treatment Strategies in HCC

December 5th 2022

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

Dr. Rhodes on Evaluating the Unmet Needs of Elderly Patients in CLL

December 2nd 2022

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

Dr. Schiller on JAK Inhibitors in Myelofibrosis

December 2nd 2022

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

Dr. Liu on ADCs Under Exploration in NSCLC

December 1st 2022

Stephen V. Liu, MD, discusses the expanding exploration of antibody-drug conjugates in non–small cell lung cancer.

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

December 1st 2022

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Pavlick on Sequencing Immunotherapy Vs Targeted Therapy in BRAF-Mutated Melanoma

December 1st 2022

Anna C. Pavlick, DO, discusses the sequencing of immunotherapy vs targeted therapy in BRAF-mutated melanoma.

Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer

November 30th 2022

Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.

Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRC

November 30th 2022

Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.

Dr. Susanibar-Adaniya on the Standard of Care for Patients With Newly Diagnosed Multiple Myeloma

November 30th 2022

Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.

Experts on the Management of Diarrhea Associated With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.

Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

November 29th 2022

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.

Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma

November 29th 2022

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.